-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
WuXi Biologics has completed nearly 20 inspections by global regulatory agencies, and as many as 13 inspections this year alone
Wuxi, October 28, 2021/PRNewswire/ - WuXi Biologics (WuXi Biologics, 2269.
This GMP inspection focused on an innovative biological drug that WuXi Biologics provides commercial production services for its global partners.
Dr.
About WuXi Biologics
WuXi Biologics (stock code: 2269.
As of June 30, 2021, 408 comprehensive projects have been developed on the WuXi Biologics platform, including 212 in the preclinical research phase, 160 in the early clinical (phase I/II) phase, and 32 in the late clinical phase ( Phase III) and 4 are in the commercial production stage
WuXi Biologics regards environment, society and governance (ESG) as an important part of business development and corporate spirit, and is committed to becoming a global ESG leader in the field of biopharmaceuticals